# Safety and Efficacy of BHV-3000 (Rimegepant) Orally Disintegrating Tablet for the Acute Treatment of Chronic Rhinosinusitis

> **NCT05248997** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 261 (actual)

## Conditions studied

- Chronic Rhinosinusitis (CRS) With and Without Nasal Polyps

## Interventions

- **DRUG:** rimegepant 75 mg ODT
- **DRUG:** Matching placebo

## Key facts

- **NCT ID:** NCT05248997
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-02-17
- **Primary completion:** 2024-03-11
- **Final completion:** 2024-04-02
- **Target enrollment:** 261 (ACTUAL)
- **Last updated:** 2025-03-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05248997

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05248997, "Safety and Efficacy of BHV-3000 (Rimegepant) Orally Disintegrating Tablet for the Acute Treatment of Chronic Rhinosinusitis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05248997. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*